Author

C. Thienpont

Observed names: C Thienpont, Chloë Thienpont, Clara Thienpont

Institution: Ziekenhuis aan de Stroom

Observed institutions: University of California, San Francisco, Universitair Ziekenhuis Leuven, Ziekenhuisnetwerk Antwerpen Stuivenberg, Ziekenhuis aan de Stroom

ORCID: 0009-0005-2263-1422

Observed ORCID: 0009-0005-2263-1422

OpenAlex ID: A5082992859

Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy

2009 · G Van Assche, C Thienpont, et al. · Gut · 176

Naturally occurring T cell mutations enhance engineered T cell therapies

2024 · Julie Garcia, Jay Daniels, et al. · Nature · 98

P422 Tofacitinib induces clinical and endoscopic remission in biologic refractory ulcerative colitis patients: a real-world Belgian cohort study

2020 · A Cremer, T Lobaton, et al. · Journal of Crohn s and Colitis · 10

Health literacy, quality of life, work productivity and activity impairment in young adults with Crohn's disease compared to diabetes mellitus patiënts: longterm follow-up from the Belgian Crohn's Disease Registry.

2019 · Constance Carels, Lucas Wauters, et al. · 1

P1157 Willingness to switch from optimized intravenous to subcutaneous infliximab in IBD: baseline characteristics from the AMARETTO trial

2026 · A Moens, T Holvoet, et al. · Journal of Crohn s and Colitis

Real-world Effectiveness and Safety of Tofacitinib in Multi-Refractory Ulcerative Colitis: insights from a Belgian Cohort with prior Anti-TNF and Vedolizumab Exposure

2025 · A Cremer, A Mansour, et al. · Acta gastro-enterologica belgica

Authors' response

2011 · Clara Thienpont, Séverine Vermeire, et al. · Gut

Works count: 7

Citation count: 285

H-index: 3

I10-index: 3